Literature DB >> 21547751

Psychometric properties of the Spanish QoL-AD with institutionalized dementia patients and their family caregivers in Spain.

B León-Salas1, R G Logsdon, J Olazarán, P Martínez-Martín.   

Abstract

OBJECTIVES: To evaluate the psychometric attributes of the Spanish version of the Quality of Life-Alzheimer's Disease Scale (QoL-AD) in institutionalized patients and family caregivers in Spain.
METHOD: 101 patients (88.1% women; mean age, 83.2  ±  6.3) with Alzheimer's disease (AD) (n = 82) and mixed dementia (n = 19) and their closest family caregivers. Patient-related variables included severity of dementia, cognitive status, perceived general health, quality of life, behavior, apathy, depression, and functional status. QoL-AD acceptability, reliability, and construct validity were analyzed.
RESULTS: The mean Mini-Mental State Examination (MMSE) score was 7.2  ±  6.1 and Global Deterioration Scale was: stage four (4%); five (21.2%); six (34.3%); and seven (40.4%). Both, QoL-AD patient version (QoL-ADp) (n = 40; MMSE = 12.0  ±  4.5) and QoL-AD caregiver version (QoL-ADc) (n = 101) lacked significant floor and ceiling effects and the Cronbach α index was 0.90 and 0.86, respectively. The corrected item-total correlation was 0.11-0.68 (QoL-ADc) and 0.28-0.84 (QoL-ADp). Stability was satisfactory for QoL-ADp (intraclass correlation coefficient [ICC]=0.83) but low for QoL-ADc (ICC = 0.51); the standard error of measurement was 2.72 and 4.69. Construct validity was moderate/high for QoL-ADc (QUALID=-0.43; EQ-5D = 0.65), but lower for QoL-ADp. No significant correlations were observed between QoL-ADp and patient variables or QoL-ADc. A low to high association (r = 0.18-0.55) was obtained between QoL-ADc and patient-related measures of neuropsychiatric, function, and cognitive status.
CONCLUSION: Differences in their psychometric attributes, and discrepancy between them, were found for QoL-ADp and QoL-ADc. In patients with AD and advanced dementia, the QoL perceived by the patient could be based on a construct that is different from the traditional QoL construct.

Entities:  

Mesh:

Year:  2011        PMID: 21547751     DOI: 10.1080/13607863.2011.562183

Source DB:  PubMed          Journal:  Aging Ment Health        ISSN: 1360-7863            Impact factor:   3.658


  5 in total

1.  Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.

Authors:  Paul B Rosenberg; Krista L Lanctôt; Lea T Drye; Nathan Herrmann; Roberta W Scherer; David L Bachman; Jacobo E Mintzer
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

2.  Change and predictors of quality of life in institutionalized older adults with dementia.

Authors:  Emilia Castro-Monteiro; Maria João Forjaz; Alba Ayala; Carmen Rodriguez-Blazquez; Gloria Fernandez-Mayoralas; Alicia Diaz-Redondo; Pablo Martinez-Martin
Journal:  Qual Life Res       Date:  2014-05-07       Impact factor: 4.147

3.  Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison.

Authors:  Samantha K Holden; Claire E Koljack; Lindsay P Prizer; Stefan H Sillau; Janis M Miyasaki; Benzi M Kluger
Journal:  Parkinsonism Relat Disord       Date:  2019-06-23       Impact factor: 4.891

4.  Reliability, validity and clinical correlates of the Quality of Life in Alzheimer's disease (QoL-AD) scale in medical inpatients.

Authors:  Gustav Torisson; Lars Stavenow; Lennart Minthon; Elisabet Londos
Journal:  Health Qual Life Outcomes       Date:  2016-06-14       Impact factor: 3.186

5.  Inter-rater agreement of the Quality of Life-Alzheimer's Disease (QoL-AD) self-rating and proxy rating scale: secondary analysis of RightTimePlaceCare data.

Authors:  Josephine Römhild; Steffen Fleischer; Gabriele Meyer; Astrid Stephan; Sandra Zwakhalen; Helena Leino-Kilpi; Adelaida Zabalegui; Kai Saks; Maria Soto-Martin; Caroline Sutcliffe; Ingalill Rahm Hallberg; Almuth Berg
Journal:  Health Qual Life Outcomes       Date:  2018-06-28       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.